Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). Objectives: To investigate the clinical response to ruxolitinib in patients with SR-cGVHD after allogeneic HSCT and to evaluate its safety profile during the treatment course. Design, Setting, and Participants: This single-center case series included 41 consecutive patients who were treated with ruxolitinib for SR-cGVHD after allogeneic HSCT between August 2017 and December 2019. Data were collected from each patient's medical record at the First Affiliated Hospital of Zhejiang University School of Medicine. Data analysis was conducted from March to May 2020. Exposure: Ruxolitinib. Main Outcomes and Measures: Treatment responses, factors associated with response, and adverse effects during ruxolitinib administration. Findings: Overall, 41 patients (median [range] age, 31 [17-56] years; 14 [34.1%] women) were treated with ruxolitinib and included in this study. A total of 15 patients (36.6%) had a complete remission, and 14 (34.1%) had a partial remission, with an overall response rate of 70.7% (29 patients; 95% CI, 56.2%-85.3%). Lung involvement (odds ratio, 0.112; 95% CI, 0.020-0.639; P = .01) and matched related donors (odds ratio, 0.149; 95% CI, 0.022-0.981; P = .048) were associated with less favorable treatment response. Major adverse events associated with ruxolitinib were cytopenias and infectious complications. The median (range) follow-up for this cohort was 14.9 (1.4-32.5) months. Prolonged survival was observed in patients with a male donor (P = .006), complete remission before transplantation (P = .02), baseline moderate cGVHD (P = .02), and skin cGVHD (P = .001). Conclusions and Relevance: In this small, single-site case series, ruxolitinib demonstrated a significant response in heavily pretreated patients with SR-cGVHD and a reasonably well-tolerated safety profile. The results add to the body of literature suggesting ruxolitinib as a promising treatment option in SR-cGVHD.
Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). Objectives: To investigate the clinical response to ruxolitinib in patients with SR-cGVHD after allogeneic HSCT and to evaluate its safety profile during the treatment course. Design, Setting, and Participants: This single-center case series included 41 consecutive patients who were treated with ruxolitinib for SR-cGVHD after allogeneic HSCT between August 2017 and December 2019. Data were collected from each patient's medical record at the First Affiliated Hospital of Zhejiang University School of Medicine. Data analysis was conducted from March to May 2020. Exposure: Ruxolitinib. Main Outcomes and Measures: Treatment responses, factors associated with response, and adverse effects during ruxolitinib administration. Findings: Overall, 41 patients (median [range] age, 31 [17-56] years; 14 [34.1%] women) were treated with ruxolitinib and included in this study. A total of 15 patients (36.6%) had a complete remission, and 14 (34.1%) had a partial remission, with an overall response rate of 70.7% (29 patients; 95% CI, 56.2%-85.3%). Lung involvement (odds ratio, 0.112; 95% CI, 0.020-0.639; P = .01) and matched related donors (odds ratio, 0.149; 95% CI, 0.022-0.981; P = .048) were associated with less favorable treatment response. Major adverse events associated with ruxolitinib were cytopenias and infectious complications. The median (range) follow-up for this cohort was 14.9 (1.4-32.5) months. Prolonged survival was observed in patients with a male donor (P = .006), complete remission before transplantation (P = .02), baseline moderate cGVHD (P = .02), and skin cGVHD (P = .001). Conclusions and Relevance: In this small, single-site case series, ruxolitinib demonstrated a significant response in heavily pretreated patients with SR-cGVHD and a reasonably well-tolerated safety profile. The results add to the body of literature suggesting ruxolitinib as a promising treatment option in SR-cGVHD.
Authors: Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Mary E D Flowers; Paul A Carpenter; Joseph Pidala; Jeanne Palmer; Mukta Arora; Madan Jagasia; Sally Arai; Corey S Cutler; Stephanie J Lee Journal: Blood Date: 2017-05-11 Impact factor: 22.113
Authors: Ayman Saad; Marcos de Lima; Sarah Anand; Vijaya Raj Bhatt; Ryan Bookout; George Chen; Daniel Couriel; Antonio Di Stasi; Areej El-Jawahri; Sergio Giralt; Jonathan Gutman; Vincent Ho; Mitchell Horwitz; Joe Hsu; Mark Juckett; Mohamed A. Kharfan-Dabaja; Alison Loren; Javier Meade; Marco Mielcarek; Jonathan Moreira; Ryotaro Nakamura; Yago Nieto; Juliana Roddy; Gowri Satyanarayana; Mark Schroeder; Carlyn Rose Tan; Dimitrios Tzachanis; Jennifer Burn; Lenora Pluchino Journal: J Natl Compr Canc Netw Date: 2020-05-01 Impact factor: 11.908
Authors: Virginia Escamilla Gómez; Valentín García-Gutiérrez; Lucía López Corral; Irene García Cadenas; Ariadna Pérez Martínez; Francisco J Márquez Malaver; Teresa Caballero-Velázquez; Pedro A González Sierra; María C Viguria Alegría; Ingrid M Parra Salinas; Cristina Calderón Cabrera; Marta González Vicent; Nancy Rodríguez Torres; Rocío Parody Porras; Christelle Ferra Coll; Guillermo Orti; David Valcárcel Ferreiras; Rafael De la Cámara LLanzá; Paula Molés; Kyra Velázquez-Kennedy; María João Mende; Dolores Caballero Barrigón; Estefanía Pérez; Rodrigo Martino Bofarull; Silvanna Saavedra Gerosa; Jorge Sierra; Marc Poch; María T Zudaire Ripa; Miguel A Díaz Pérez; Blanca Molina Angulo; Isabel Sánchez Ortega; Jaime Sanz Caballer; Juan Montoro Gómez; Ildefonso Espigado Tocino; José A Pérez-Simón Journal: Bone Marrow Transplant Date: 2019-11-07 Impact factor: 5.483
Authors: Robert Q Le; Xin Wang; Hongfei Zhang; Hongshan Li; Donna Przepiorka; Jonathon Vallejo; Ruby Leong; Lian Ma; Kirsten B Goldberg; Richard Pazdur; Marc R Theoret; Angelo De Claro Journal: Oncologist Date: 2022-06-08 Impact factor: 5.837
Authors: Cong Wei; Xiaoting Zhang; Dan Liang; Jilong Yang; Jingwen Du; Chunyan Yue; Lan Deng Journal: Drug Des Devel Ther Date: 2021-11-30 Impact factor: 4.162
Authors: Rachael C Adams; Dylan Carter-Cusack; Samreen N Shaikh; Genesis T Llanes; Rebecca L Johnston; Gregory Quaife-Ryan; Glen Boyle; Lambros T Koufariotis; Andreas Möller; Bruce R Blazar; Jana Vukovic; Kelli P A MacDonald Journal: Blood Date: 2022-03-03 Impact factor: 25.476